

# Clinical Note

**Patient Name:** Mary Johnson

**Date of Birth:** 1958-07-22

**Date of Note:** November 18, 2025

## Diagnosis & Disease Status

**Primary Diagnosis:** Breast cancer

**ICD-10 Code:** C50.919

**Disease Stage:** Stage II (Note: Assumed, HER2+ with surgery/chemo history)

**Performance Status:** ECOG 1

## Clinical History

**Prior Therapies:**

- Surgery and/or chemotherapy

**Current Line of Therapy:**

- Adjuvant

**Medication History:**

- Surgery
- Chemotherapy

## Biomarker & Laboratory Results

Biomarker / Test	Result	Comments
HER2 IHC	3+ (Positive)	Eligible for trastuzumab

## Assessment & Plan

**Assessment:**

Patient with Stage II breast cancer, status post-surgery/chemotherapy. Biomarker testing indicates HER2 positive (IHC 3+) status, confirming eligibility for targeted anti-HER2 therapy in the adjuvant setting.

**Treatment Plan:**

- Planned Treatment:** Trastuzumab

## **Insurance Information**

Provider: Aetna

Policy ID: INS67890

Coverage Period: 2025-01-01 to 2025-12-31

Eligibility Status: ACTIVE